We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis

By LabMedica International staff writers
Posted on 27 Jan 2025
Print article
Image: The diagnostic sensitivity of the interferon-γ release assay was higher in patients with COPD complicated with active pulmonary tuberculosis (Photo courtesy of Adobe Stock)
Image: The diagnostic sensitivity of the interferon-γ release assay was higher in patients with COPD complicated with active pulmonary tuberculosis (Photo courtesy of Adobe Stock)

Chronic obstructive pulmonary disease (COPD) is a common respiratory condition and a major chronic lung disease that significantly impacts public health and work capacity. Long-term respiratory infections in COPD patients can weaken local respiratory immunity. Due to their immunosuppressive status and frequent corticosteroid use, COPD patients are more vulnerable to developing pulmonary tuberculosis. Conventional diagnostic methods for tuberculosis have shown decreased sensitivity in COPD patients, highlighting the need for more effective diagnostic tests that are easily accessible, well-accepted, simple to administer, and, most importantly, more sensitive in detecting tuberculosis. In a new study, an interferon-γ release assay has demonstrated higher diagnostic sensitivity in COPD patients with pulmonary tuberculosis than other diagnostic methods.

The nested case-control study, conducted between January 2019 and June 2021 at the Fifth Hospital of Shijiazhuang (Hebei, China), involved 123 COPD patients. Thirty-one patients with active pulmonary tuberculosis and COPD formed the observation group (Group A), 31 with nonactive pulmonary tuberculosis and COPD made up the COPD control group (Group B), and 31 patients with active pulmonary tuberculosis without COPD were the non-COPD control group (Group C). Diagnostic tests including interferon-γ release assay, purified protein derivative of tuberculin (PPD) test, anti-tuberculosis antibody test, sputum smear microscopy, and PCR for Mycobacterium tuberculosis were administered to each group. The researchers compared the positive detection rates from all five diagnostic methods.

The results, published in BMC Infectious Diseases, showed that the interferon-γ release assay had higher diagnostic sensitivity for active pulmonary tuberculosis in COPD patients than sputum smear microscopy, PCR, or serum anti-tuberculosis antibody tests. COPD complications did not impact the T-SPOT test results, and higher T-SPOT values indicated a greater likelihood of active tuberculosis. Based on these findings, the researchers recommend that T-SPOT-positive patients, who are clinically considered to have inactive tuberculosis, undergo regular follow-ups to monitor any changes in their condition.

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Coagulation Analyzer
CS-2400

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.